NASDAQ:ALKS

Alkermes Stock Forecast, Price & News

$22.29

-0.56 (-2.45 %)

(As of 01/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$22.03

Now: $22.29▼

$23.02

50-Day Range

$18.35

MA: $20.86▼

$22.85

52-Week Range

$11.98

Now: $22.29▼

$23.02

Volume1.87 million shs

Average Volume1.54 million shs

Market Capitalization$3.55 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.25

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

MarketRank^™

Overall MarketRank^™

1.23 out of 5 stars

Medical Sector

776th out of 1,928 stocks

Pharmaceutical Preparations Industry

390th out of 774 stocks

1.1 Analyst's Opinion

Consensus Rating
Alkermes has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 2 buy ratings, 7 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $21.09, Alkermes has a forecasted downside of 5.4% from its current price of $22.29.
Amount of Analyst Coverage
Alkermes has only been the subject of 2 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Alkermes has received 637 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Alkermes has received 488 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Alkermes has received 56.62% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote “Outperform” if you believe ALKS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Alkermes does not currently pay a dividend.
Dividend Growth
Alkermes does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alkermes insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.49% of the stock of Alkermes is held by insiders.
Percentage Held by Institutions
97.30% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Alkermes are expected to grow in the coming year, from ($0.16) to $0.07 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alkermes is -48.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alkermes is -48.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Alkermes has a PEG Ratio of 12.74. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Alkermes has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:ALKS

Previous Symbol

CUSIPG0176710

CIK1520262

Webwww.alkermes.com

Phone353-1772-8000

Employees2,235

Debt

Debt-to-Equity Ratio0.25

Current Ratio2.71

Quick Ratio2.39

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E Growth12.74

Sales & Book Value

Annual Sales$1.17 billion

Price / Sales3.03

Cash Flow$0.59 per share

Price / Cash Flow37.52

Book Value$6.89 per share

Price / Book3.24

Profitability

EPS (Most Recent Fiscal Year)$0.07

Net Income$-196,620,000.00

Net Margins-6.28%

Return on Equity9.35%

Return on Assets5.50%

Miscellaneous

Outstanding Shares159,150,000

Market Cap$3.55 billion

Next Earnings Date2/11/2021 (Estimated)

OptionableOptionable

$22.29

-0.56 (-2.45 %)

(As of 01/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

How has Alkermes' stock been impacted by Coronavirus (COVID-19)?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALKS shares have increased by 37.2% and is now trading at $22.29.
View which stocks have been most impacted by COVID-19.

Is Alkermes a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Alkermes?

Wall Street analysts have given Alkermes a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alkermes wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Alkermes' CEO?

1,428 employees have rated Alkermes CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Alkermes' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Alkermes.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) posted its quarterly earnings data on Thursday, October, 29th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.40. The firm had revenue of $265 million for the quarter, compared to analyst estimates of $238.39 million. Alkermes had a positive return on equity of 9.35% and a negative net margin of 6.28%. Alkermes's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) EPS.
View Alkermes' earnings history.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY20 earnings guidance on Thursday, October, 29th. The company provided earnings per share (EPS) guidance of $0.31-0.43 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.10. The company issued revenue guidance of $1.01-1.04 billion, compared to the consensus revenue estimate of $982.45 million.

What price target have analysts set for ALKS?

10 analysts have issued 1-year price objectives for Alkermes' shares. Their forecasts range from $15.00 to $28.00. On average, they anticipate Alkermes' stock price to reach $21.09 in the next twelve months. This suggests that the stock has a possible downside of 5.4%.
View analysts' price targets for Alkermes or view Wall Street analyst' top-rated stocks.

Who are some of Alkermes' key competitors?

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all of ALKS's competitors.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Who are Alkermes' key executives?

Alkermes' management team includes the following people:

Mr. Richard F. Pops, Chairman & CEO (Age 59, Pay $2.03M)
Dr. Floyd E. Bloom, Founder (Age 84, Pay $57.73k)
Mr. James M. Frates, Sr. VP & CFO (Age 54, Pay $848k)
Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 49, Pay $907.75k)
Mr. Michael J. Landine, Sr. VP of Corp. Devel. & Chief Risk Officer (Age 67, Pay $762.5k)
Dr. Craig C. Hopkinson, Exec. VP of R&D and Chief Medical Officer (Age 53, Pay $1.02M)
Mr. Iain Michael Brown, Sr. VP of Fin. & Chief Accounting Officer (Age 52)
Ms. Sandra Coombs, Co-Head of Investor Relations
Eva Stroynowski, VP of Product & R&D Communications, Public Affairs
Mr. Stephen Schiavo, Sr. VP of HR

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by many different institutional and retail investors. Top institutional shareholders include Meditor Group Ltd (0.38%), Rhenman & Partners Asset Management AB (0.13%), Diversified Trust Co (0.01%) and Pacer Advisors Inc. (0.00%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops.
View institutional ownership trends for Alkermes.

Which institutional investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd, and Rhenman & Partners Asset Management AB. Company insiders that have sold Alkermes company stock in the last year include David W Anstice, Iain Michael Brown, Michael J Landine, and Richard F Pops.
View insider buying and selling activity for Alkermes or view top insider-selling stocks.

Which institutional investors are buying Alkermes stock?

ALKS stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Pacer Advisors Inc..
View insider buying and selling activity for Alkermes or or view top insider-buying stocks.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $22.29.

How big of a company is Alkermes?

Alkermes has a market capitalization of $3.55 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

What is Alkermes' official website?

The official website for Alkermes is www.alkermes.com.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here